Skip to Content
Merck
CN
All Photos(1)

Documents

Safety Information

O9387

Sigma-Aldrich

Oxatomide

≥99%

Synonym(s):

1-[3-[4-(Diphenylmethyl)-1-piperazinyl]propyl]-1,3-dihydro-2H-benzimidazol-2-one

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C27H30N4O
CAS Number:
60607-34-3
Molecular Weight:
426.55
EC Number:
262-320-9
MDL number:
MFCD00211147
UNSPSC Code:
51111800
PubChem Substance ID:
24278615
NACRES:
NA.77

Quality Level

100

Assay

≥99%

form

powder

color

white

solubility

DMSO: soluble
ethanol: soluble

originator

Johnson & Johnson

SMILES string

O=C1Nc2ccccc2N1CCCN3CCN(CC3)C(c4ccccc4)c5ccccc5

InChI

1S/C27H30N4O/c32-27-28-24-14-7-8-15-25(24)31(27)17-9-16-29-18-20-30(21-19-29)26(22-10-3-1-4-11-22)23-12-5-2-6-13-23/h1-8,10-15,26H,9,16-21H2,(H,28,32)

InChI key

BAINIUMDFURPJM-UHFFFAOYSA-N

Gene Information

human ... DRD3(1814)

General description

Oxatomide, a histamine H1-receptor antagonist, is bound at high levels to plasma proteins in human blood.

Biochem/physiol Actions

Oxatomide, found in several antihistamines, can suppress mast cell degranulation. It can be used as an alternative to individuals with allergic rhinitis who do not or poorly respond to more established antihistamines. Oxatomide exhibits both antihistamine and anti-inflammatory properties. It exhibits therapeutic effects against asthma and vulvar lichen sclerosus.
Oxatomide is an anti-allergy compound. It suppresses platelet activating factor (PAF)-induced bronchoconstriction and inhibits leukotriene production.

Features and Benefits

This compound was developed by Johnson & Johnson. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H302

Hazard Classifications

Acute Tox. 4 Oral

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Regulatory Information

新产品

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

C Dani et al.
Drugs under experimental and clinical research, 28(5), 207-210 (2003-03-15)
The pharmacokinetics and tolerability of oxatomide oral suspension were investigated in preterm infants to evaluate the feasibility of planning a further study to assess its antiinflammatory effects and its effectiveness in preventing chronic lung disease (CLD). Following the administration of
M Origoni et al.
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 55(3), 259-264 (1996-12-01)
The treatment of vulvar lichen sclerosus has greatly improved in recent years, with the introduction of new pharmacological approaches and reconsideration of the traditional ones. Oxatomide is a molecule with both antihistamine and inhibiting activities for the inflammatory response, which
Yong-Soo Park et al.
The Laryngoscope, 116(9), 1642-1646 (2006-09-07)
Inflammatory mediators (IMs) play a major role in the production of middle ear effusion (MEE). Tumor necrosis factor (TNF)-alpha and leukotrienes (LTs) appear to be important in the pathogenesis of otitis media with effusion (OME). The purpose of this study
D M Richards et al.
Drugs, 27(3), 210-231 (1984-03-01)
Oxatomide is an orally active H1-histamine receptor antagonist which, as appears to occur with some other antihistamines, also inhibits mast cell degranulation. Oxatomide has demonstrated response rates similar to those with other more established members of its drug class in
Gunnar M Buyse et al.
European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society, 11(6), 337-340 (2007-04-27)
The authors report a pilot open-label two-center therapeutic trial of oxatomide in 14 steroid-naive DMD boys aged 5-10 years. Comparison of linear evolutions between 3 months medication-free lead-in periods and 6 months treatment periods showed no significant differences in quantitative
View All Related Papers

Articles

Bioactive Molecules for Immunology Research

Bioactive small molecules for immune system signaling target identification/validation and antibiotics, antivirals, and antifungals offered.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service